TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16650294
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of midazolam and meperidine
Study: 16650294
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no sedation or analgesic)
Study: 11530870
Drug: Dexamethasone (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (24 mg divided into 4 doses 12 hours apart)
Study: 11367651
Drug: Qingning Oral
Normalized name: PYRROLIDINYL DIAMINOPYRIMIDINE OXIDE 33 g in 100 mL / PANAX GINSENG WHOLE 33 g in 100 mL / DIAMINOPYRIMIDINE OXIDE 30 g in 100 mL / NIACINAMIDE 33 g in 100 mL INTRADERMAL LIQUID [QINGLIN ANTI DETACHMENT NURTURING HAIR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingning Oral Liquid (QNOL) with conventional therapy, 10 ml three times a day for 30 days
Study: 8150234
Drug: Cholecystokinin-33 infusion
Normalized name: cholecystokinin
DrugBank: Cholecystokinin (DB08862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecystokinin-33 infusion (0.25 Ivy Dog Unit.kg‐1.h‐1) during hyperglycaemia
Study: 8150234
Drug: Cholecystokinin-33 infusion
Normalized name: cholecystokinin
DrugBank: Cholecystokinin (DB08862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecystokinin-33 infusion (0.5 Ivy Dog Unit.kg‐1.h‐1) during hyperglycaemia
Study: 8150234
Drug: Cholecystokinin-33 infusion
Normalized name: cholecystokinin
DrugBank: Cholecystokinin (DB08862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecystokinin-33 infusion (1.0 Ivy Dog Unit.kg‐1.h‐1) during hyperglycaemia
Study: 22617307
Drug: Antibiotics +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics + Proxelan for 28 days
Study: 22617307
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for 28 days
Study: 18544384
Drug: Local wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local wound infusion of 0.15% bupivacaine at 2 mL/h combined with intravenous patient-controlled analgesia
Study: 18544384
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia alone with sham thoracotomy wound infusion of normal saline
Study: 9988841
Drug: New antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antipsychotics (risperidone, olanzapine, sertindole, quetiapine)
Study: 9988841
Drug: All new
Approvals — FDA: no, EMA: no, PMDA: no
Description: All new antipsychotics
Study: 7734250
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose group
Study: 31590924
Drug: FAAH inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAAH inhibitor (PF‐04457845, 4 mg orally, once daily)
Study: 27940278
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen (2 L/min via standard nasal prongs) during the 6-min walk test (6MWTO2)
Study: 25661195
Drug: MK-7123 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-7123 (30 mg, po, daily for 28 days)
Study: 23417515
Drug: Ziprasidone 60
Normalized name: ziprasidone 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 60 mg twice daily
Study: 21795435
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion (0.12 g · kg(‐1) · h(‐1))
Study: 17324660
Drug: Ginkgo biloba-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba-based supplement (160 mg ginkgo biloba, 68 mg gotu kola, and 180 mg DHA per day for 4 months)
Study: 16442038
Drug: Onion extract
Normalized name: Onion Extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onion extract gel (Mederma) applied three times daily for 8 weeks
Study: 16442038
Drug: Petrolatum-based emollient
Normalized name: PETROLATUM BASE
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petrolatum-based emollient (Aquaphor) applied three times daily for 8 weeks
Study: 9034695
Drug: Right unilateral
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right unilateral (RUL) electroconvulsive therapy (ECT)
Study: 1355427
Drug: alcohol (0.72
Approvals — FDA: no, EMA: no, PMDA: no
Description: alcohol (0.72 g.kg‐1, lean body mass)
Study: 6438504
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy without initial angiography
Study: 25628006
Drug: JDTic 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: JDTic 1 mg
Study: 16885722
Drug: Single 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 10 mg oral dose of dronabinol (synthetic THC)
Study: 16885722
Drug: Multiple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of THC (0.39, 0.47, and 14.8 mg THC in hemp oil and 7.5 mg dronabinol)
Study: 15595301
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine (Cr) 0.2 g Cr x kg(‐1) after exercise
Study: 8390732
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving perioperative parenteral antibiotics only
Study: 31664632
Drug: 80% Aloe
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80% Aloe Vera gel
Study: 31664632
Drug: 0.12% Chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% Chlorhexidine gel
Study: 30581291
Drug: Dopamine (DA)-blocking
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (DA)-blocking drug
Study: 28958469
Drug: Lenalidomide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (2.5 mg/day)
Study: 28958469
Drug: Placebo (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2.5 mg/day)
Study: 24734355
Drug: 6 hours
Normalized name: nitroglycerin 0.6 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 hours Chlorhexidine (CHX) 0.5% oral decontamination
Study: 24734355
Drug: 12 hours
Normalized name: PATCH, TRANSDERMAL 12 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 hours Chlorhexidine (CHX) 0.5% oral decontamination
Study: 18000094
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg daily of micronized DHEA
Study: 17095898
Drug: Topiramate (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (average dosage 5.2 mg/kg per day)
Study: 12907482
Drug: Heroin plus
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin plus methadone (maximum 1000 mg heroin per day and 150 mg methadone per day)
Study: 12907482
Drug: Injectable heroin
Normalized name: heroin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable heroin plus methadone (maximum 1000 mg heroin per day and 150 mg methadone per day)
Study: 12907482
Drug: Methadone alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone alone (maximum 150 mg per day)
Study: 8682597
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 60-90 mg o.d.
Study: 8682597
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 40-60 mg b.d.
Study: 8682597
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate 50-100 mg o.d.
Study: 1992535
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (320 to 1,600 mg/d)
Study: 31620886
Drug: Heat-killed Lactobacillus
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-killed Lactobacillus plantarum L-137 (10 mg)
Study: 22784345
Drug: Ginger combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger combination (340 mg EV.EXT 35 Zingiber officinalis extract)
Study: 22784345
Drug: Diclofenac (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (100 mg daily)
Study: 20357732
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (captopril and enalapril)
Study: 20357732
Drug: Combined immunosuppressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined immunosuppressants for crescentic poststreptococcal glomerulonephritis
Study: 15616085
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (GA) and postoperative opioid analgesia (morphine 0.1 mg/kg bolus and patient‐controlled infusion)
Study: 15616085
Drug: GA and
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA and paravertebral anesthesia and analgesia (PVAA) (72‐h infusion)
Study: 15616085
Drug: GA and
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA and postoperative opioid analgesia (morphine 0.1 mg/kg bolus and patient‐controlled infusion)
Study: 8560160
Drug: 0.05% levocabastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% levocabastine nasal spray, twice daily for four weeks
Study: 8560160
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray, twice daily for four weeks
Study: 2231883
Drug: Carboplatin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (400 mg/m² every 28 days)
Study: 2231883
Drug: CHIP (270
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHIP (270 mg/m² every 28 days)
Study: 673643
Drug: Rational-emotive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational-emotive therapy with rational-emotive imagery
Study: 673643
Drug: Rational-emotive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational-emotive therapy without imagery
Study: 27807903
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate 4.5 g
Study: 27807903
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate 6 g
Study: 27807903
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate 9 g
Study: 26303520
Drug: Perioperative antibiotic
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative antibiotic prophylaxis with ciprofloxacin 2 × 500 mg p.o. for 5 days
Study: 26303520
Drug: No perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No perioperative antibiotic prophylaxis
Study: 18573923
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management alone (MedMgt)
Study: 18573923
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy alone (Beh)
Study: 18573923
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of medication management and behavior therapy (Comb)
Study: 18573923
Drug: Community comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community comparison of treatment 'as usual' (CC)
Study: 16491266
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg BH4
Study: 16491266
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg BH4
Study: 12919178
Drug: Zolpidem (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (5 mg oral dose) in elderly men
Study: 12919178
Drug: Zolpidem (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (5 mg oral dose) in young men
Study: 12919178
Drug: Zolpidem (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (5 mg oral dose) in elderly women
Study: 12919178
Drug: Zolpidem (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (5 mg oral dose) in young women
Study: 9203230
Drug: m-Chlorophenylpiperazine (mCPP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-Chlorophenylpiperazine (mCPP, 0.1 mg/kg)
Study: 8202885
Drug: Combined nebulised
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined nebulised salbutamol (5 mg/dose) and aminophylline infusion (0.6‐0.9 mg/kg/hour)
Study: 8202885
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (salbutamol + aminophylline)
Study: 3300103
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy with MTX and 5-FU followed by systemic CMFV chemotherapy (therapy arm A)
Study: 3300103
Drug: Systemic CMFV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic CMFV chemotherapy only (therapy arm B)
Study: 25909788
Drug: Cellex (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellex (0.1 mg subcutaneously once a day for the first 10 days and from 21 to 27 days)
Study: 23355629
Drug: Olmesartan (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (10-40 mg daily)
Study: 23355629
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (not including ARBs or ACE inhibitors)
Study: 19679450
Drug: 1 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Hz rTMS treatment of the left temporo‐parietal region
Study: 19679450
Drug: 1 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Hz rTMS treatment of the bilateral temporo‐parietal regions
Study: 19679450
Drug: Combined rTMS
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined rTMS treatment (bilateral and left)
Study: 10773500
Drug: Dolasetron 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron 25 mg
Study: 14595183
Drug: Dolasetron 50
Normalized name: dolasetron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron 50 mg
Study: 1795004
Drug: Oral ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ifosfamide (1 g/m2 or 1.5 g/m2)
Study: 1795004
Drug: Intravenous ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ifosfamide (1 g/m2 or 1.5 g/m2)
Study: 1795004
Drug: Oral ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ifosfamide
Study: 1795004
Drug: Intravenous ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ifosfamide
Study: 6321674
Drug: Synthetic long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic long-acting ACTH (1 mg IM given 24 hours, 12 hours, and immediately preceding cisplatin)
Study: 6321674
Drug: Chlorpromazine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (50 mg IM)
Study: 31672419
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal dexmedetomidine 0.5 µg.kg−1 (Group DEX I)
Study: 31672419
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal dexmedetomidine 1 µg.kg−1 (Group DEX II)
Study: 31672419
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal dexmedetomidine (both DEX I and DEX II)
Study: 28901678
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) based treatment as usual
Study: 21605352
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (laser iridotomy surgery and medical treatment)
Study: 19397664
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (Aqueous)
Study: 16940886
Drug: Omeprazole 60
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 60 mg + pancreatic enzymes 10,000 IU lipase tid (treatment A)
Study: 16940886
Drug: Omeprazole 60
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 60 mg + pancreatic enzymes 20,000 IU lipase tid (treatment B)
Study: 3995531
Drug: Clebopride (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clebopride (2 mg)
Study: 30926986
Drug: Decaffeinated green
Normalized name: (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT) [DSC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated green tea extract (GTE) - 4 capsules containing 1315 mg total catechins including 843 mg epigallocatechin‐3‐gallate daily for 1 year
Study: 30926986
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - similar capsules containing no tea catechins
Study: 28427299
Drug: Low-frequency rTMS
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency rTMS + Physical Therapy (PT)
Study: 24866258
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention on folic acid (FA) supplements at the 6-month visit.
Study: 21654755
Drug: Azelnidipine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelnidipine (8 mg/day increased to 16 mg/day)
Study: 21654755
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 mg/day increased to 5 mg/day)
Study: 9180240
Drug: Atorvastatin (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (2.5, 5, 10, 20, 40, or 80 mg/day)
Study: 8299665
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of powdered garlic (coated tablets) daily for 4 weeks
Study: 24358287
Drug: Hypnotic suggestion
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestion of ingesting an appetizing meal
Study: 24358287
Drug: Hypnotic suggestion
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestion of ingesting an unappetizing meal
Study: 16627459
Drug: Ramp therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramp therapy
Study: 16627459
Drug: Medication toxicity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication toxicity
Study: 2677123
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments for C. pylori gastritis and NUD
Study: 309095
Drug: Combined prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined prednisone (29 mg/day) and cyclophosphamide (107 mg/day) for six months
Study: 309095
Drug: Prednisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (40 mg/day) for six months
Study: 21550959
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro mix 75/25
Study: 21550959
Drug: Metformin/thiazolidinedione
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin/thiazolidinedione
Study: 21550959
Drug: Metformin/sulfonylurea/thiazolidinedione
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin/sulfonylurea/thiazolidinedione
Study: 16541243
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg caffeine
Study: 16541243
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg caffeine
Study: 3222359
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg caffeine (control)
Study: 16541243
Drug: All caffeine
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All caffeine doses (50, 150, 450 mg)
Study: 3793549
Drug: 60 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/m2 of doxorubicin every 3 weeks for eight courses
Study: 3793549
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (optional)
Study: 26522923
Drug: Pulmonary Rehabilitation
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary Rehabilitation plus hyperproteic oral nutritional supplement enriched with HMB (PRONS)
Study: 24439972
Drug: Triple Pill
Normalized name: Triple Wormer Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple Pill (initially strength 1-telmisartan 20 mg, amlodipine 2.5 mg, hydrochlorothiazide 6.25 mg, with the option of subsequent titration to strength 2-telmisartan 40 mg, amlodipine 5 mg, hydrochlorothiazide 12.5 mg)
Study: 15999098
Drug: Fixed-dose rate
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose rate gemcitabine
Study: 12453952
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg glipizide (30 min premeal)
Study: 12453952
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg nateglinide (15 min premeal)
Study: 12453952
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg glipizide plus 120 mg nateglinide (30 and 15 min premeal, respectively)
Study: 9768208
Drug: Heberbiovac HB
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heberbiovac HB vaccine
Study: 9768208
Drug: Engerix-B vaccine
Normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix-B vaccine (control)
Study: 30080248
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of unfavorable criteria
Study: 27084855
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin 1 gm, 1 hour preoperatively and 2 gm for 2 days postoperatively (Test group)
Study: 24799054
Drug: trastuzumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: trastuzumab (4 mg/kg), gemcitabine (1000 mg/m(2)), docetaxel (50 mg/m(2))
Study: 18758336
Drug: New mothers'
Approvals — FDA: no, EMA: no, PMDA: no
Description: New mothers' support group with one-on-one teaching prenatally and weekly meetings postpartum, taught by a lactation consultant and a pediatrician
Study: 22814329
Drug: Intravenous amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amphotericin B lipid complex (ABLC) 7.5 mg/kg weekly